JBS Science, cu sediul în Pennsylvania, a declarat astăzi că a primit 3 milioane USD Bridge Award for Small Business Innovation Research IIB de la Institutul Național al Cancerului. Compania a dezvoltat primul produs de biopsie lichidă, care este screeningul ADN-ului urinar pentru cancerul precoce al celulelor hepatice (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of cancer de ficat. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumoare DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS a declarat că a cooperat cu James Hamilton de la Centrul Medical al Universității Johns Hopkins și cu Hie-Won Hann de la Spitalul Universitar Thomas pentru a promova dezvoltarea testului de urină pentru cancerul hepatic.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
